TESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
October 25, 2017 19:15 ET
|
TESARO, Inc.
VARUBI injectable emulsion features a ready-to-use, single-dose vial for intravenous administrationAvailability of new formulation offers healthcare providers the flexibility to choose oral or IV...
TESARO Provides Business and Pipeline Update at ASCO Investor Briefing
June 03, 2017 18:30 ET
|
TESARO, Inc.
Initial TOPACIO data for niraparib plus KEYTRUDA® is indicative of potentially synergistic anti-tumor activity in platinum-resistant ovarian cancerPhase 1 results for TSR-042 show anti-PD-1...
TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission
April 26, 2017 08:30 ET
|
TESARO, Inc.
VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimenUp to 50% of patients undergoing highly or moderately...
TESARO Announces Fourth-Quarter 2016 Operating Results
February 28, 2017 16:05 ET
|
TESARO, Inc.
Niraparib NDA under review by FDA; pre-launch preparations for planned commercial launch well underwayExpanded access program (EAP) for niraparib open in U.S.; European EAP expected to open 1H...
TESARO Receives Positive CHMP Opinion for VARUBY®
February 27, 2017 02:00 ET
|
TESARO, Inc.
WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for...
TESARO Outlines Business Priorities and Strategic Outlook for 2016
January 11, 2016 08:15 ET
|
TESARO, Inc.
U.S. commercial launch of VARUBI™ (oral rolapitant) well underwayData from niraparib NOVA and QUADRA registration trials expected in Q2 2016 Niraparib New Drug Application (NDA) submission planned...